ESR1 and breast carcinoma: These results indicated that the targeted HRP formulation successfully recognized the estrogen receptor of breast cancer cells and released a higher amount of DOX in the hypoxic conditions of the tumor, thereby augmenting the anticancer effects of DOX [129].